[2] Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning.

"[3] On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

[4] Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors.

[14] However, the company also had an office in Denmark, in which it received a crucial part of its early investments[14][15] from BankInvest,[15] under managing director Florian Schönharting,[16][17][18] Kommunernes Pensionsforsikring A/S[15] and Dansk Kapitalanlæg Aktieselskab[15] as well as private investor Lars Christiansen.

[24] In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals.